Press release Biocartis Group NV: Disclosure of a transparency notification
02 Dezember 2022 - 05:45PM
GlobeNewswire Inc.
Press release Biocartis Group NV: Disclosure of a transparency
notification
PRESS RELEASE: REGULATED INFORMATION
2
December 2022, 17:45 CET
Disclosure of a transparency
notification
Mechelen, Belgium,
2 December 2022
– Biocartis Group NV (the "Company" or
"Biocartis"), an innovative molecular diagnostics
company (Euronext Brussels: BCART), announces today, in accordance
with Article 14, paragraph 1 of the Belgian Act of 2 May 2007
on the disclosure of major shareholdings in issuers of which shares
are admitted to trading on a regulated market and laying down
miscellaneous provisions (the "Belgian Transparency
Act"), that it received a transparency notification dated
29 November 2022 (the "Notification") indicating
that on 24 November 2022 the aggregate number of voting rights and
equivalent financial instruments held by Credit Suisse (Schweiz)
AG, a subsidiary of Credit Suisse Group AG, increased to 3.62%, as
further explained below. The Notification is based on a denominator
amounting to 58,416,956, disclosed by the press release dated 28
October 2022. It is to be noted that the denominator as of today
amounts to 92,061,563.
The Notification contains the following
information:
- Reason for the
Notification: Acquisition or disposal of voting securities
or voting rights.
- Notification by: A
parent undertaking or a controlling person.
- Person subject to the
notification requirement: Credit Suisse Group AG,
Paradeplatz 8, CH-8001 Zürich, Switzerland.
- Transaction date:
24 November 2022.
- Threshold that is
crossed: 3%.
- Denominator: 58,416,956.
- Details of the
Notification: The Notification sets out that it concerns a
group notification with a crossing of the 3% threshold at
subsidiary level. Credit Suisse (Schweiz) AG, a subsidiary of
Credit Suisse Group AG, now holds an aggregate number of
2,112,084 voting rights and equivalent financial instruments (i.e.,
shares which it has out on loan to third parties with a right to
recall). The parent company Credit Suisse Group AG now has an
aggregate position of 3.62% (as compared to 3.68% notified to
Biocartis on 2 February 2022).
- Full chain of controlled
undertakings through which the holding is effectively
being held: Credit Suisse Group AG,
Credit Suisse AG, Credit Suisse (Schweiz) AG.
For further information, reference is made to
the Notification which is available here on the Biocartis
website.
Pursuant to the Belgian Transparency Act and the
articles of association of the Company, a notification to the
Company and the Belgian Financial Services and Markets Authority
(‘FSMA’) is required by all natural and legal persons in each case
where the percentage of voting rights in the Company held by such
persons reaches, exceeds or falls below the threshold of 3%, 5%,
10%, and every subsequent multiple of 5%, of the total number of
voting rights in the Company.
--- END ---
More information: Renate
DegraveHead of Corporate Communications & Investor Relations
Biocartise-mail rdegrave@biocartis.com tel
+32 15 631 729
mobile +32 471 53 60 64
About Biocartis
With its revolutionary and proprietary Idylla™
platform, Biocartis (Euronext Brussels: BCART) aspires to enable
personalized medicine for patients around the world through
universal access to molecular testing, by making molecular testing
actionable, convenient, fast and suitable for any lab. The Idylla™
platform is a fully automated sample-to-result, real-time PCR
(Polymerase Chain Reaction) based system designed to offer in-house
access to accurate molecular information in a minimum amount of
time for faster, informed treatment decisions. Idylla™'s
continuously expanding menu of molecular diagnostic tests address
key unmet clinical needs, with a focus in oncology. This is the
fastest growing segment of the molecular diagnostics market
worldwide. Today, Biocartis offers tests supporting melanoma,
colorectal, lung and liver cancer, as well as for COVID-19, Flu,
RSV and sepsis. For more information, visit www.biocartis.com
or follow Biocartis on Twitter @Biocartis_ , Facebook or
LinkedIn.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product. This press release is not
for distribution, directly or indirectly, in any jurisdiction where
to do so would be unlawful. Any persons reading this press release
should inform themselves of and observe any such restrictions.
Biocartis takes no responsibility for any violation of any such
restrictions by any person. This press release does not constitute
an offer or invitation for the sale or purchase of securities in
any jurisdiction. No securities of Biocartis may be offered or sold
in the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2023 bis Apr 2023
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Apr 2022 bis Apr 2023